Takeda Targets Infection Risk in Multiple Myeloma With New Gammagard Phase 3 Study
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The phase 3 study “A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation AntigenxCD3-Directed Bispecific Antibody Therapy” tests if early use of Gammagard Liquid can better prevent infections in adults with multiple myeloma on advanced antibody drugs. This matters because infections are a major cause of treatment delays, hospital stays, and costs in this fast growing cancer segment.
The treatment under review is Gammagard Liquid, also called IGI, 10%, TAK-339, or KIOVIG, given as an intravenous infusion. It is a human immune globulin product designed to boost patients’ immune defense and lower the risk of serious infections while they receive BCMAxCD3 bispecific antibody therapy.
The trial is interventional and randomized, which means patients are assigned by chance to one of two care paths. It uses a parallel design with no blinding, so both doctors and patients know which infection prevention strategy they receive, and the main goal is to see which approach better prevents infections in real world practice.
One group receives Gammagard regularly as primary prevention for up to 12 months, while the other group starts Gammagard only after a serious infection occurs. Clinic visits occur every 3 or 4 weeks, and total time on study can reach about 14 months including screening, which offers a sizable window to gather safety and infection outcome data.
The study is sponsored by Takeda and its affiliates, including Takeda Development Center Americas, Inc. and Baxalta Innovations GmbH, now part of Takeda, signaling a strategic push to defend and expand the company’s immunoglobulin and oncology support portfolio as bispecific antibodies gain wider use.
The trial is listed as recruiting, with initial submission dated May 13, 2025, suggesting startup activities are underway at multiple sites. The latest update on February 19, 2026, confirms active management and protocol refinement, while primary and final completion dates are not yet posted, so investors should treat this as an early to mid stage development signal rather than a near term revenue event.
For Takeda (TAK), positive outcomes could support broader use of Gammagard in multiple myeloma and possibly other bispecific antibody settings, reinforcing recurring revenue from its established immunoglobulin franchise. A strong data set could also differentiate Takeda in supportive oncology care, adding a defensive stream of cash flows that may appeal to yield oriented investors.
Competitors in immunoglobulins and oncology support, such as CSL and Grifols, are also seeking ways to lock in demand as complex therapies move into earlier treatment lines. If this trial shows a clear benefit for primary prevention, it could shift practice patterns toward earlier and more regular IVIG use, which would favor scale players like Takeda with broad manufacturing and distribution capacity.
Near term, the update is more about pipeline depth and strategic positioning than immediate earnings impact, so major stock moves may wait for interim or final data. Still, the fact that Takeda is investing in infection prevention for cutting edge myeloma therapies should be seen as a sign of long term commitment to high value, specialty care markets rather than one off oncology bets.
The study remains active and recruiting with updated details available on the ClinicalTrials portal, where investors can track progress and future data releases.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
